Floatz logo

Irinotecan

Urinary Bladder Neoplasms

Merck Sharp & Dohme LLCSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Urinary Bladder Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Merck Sharp & Dohme LLC
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Eli Lilly and Company
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 2BB
Cyclophosphamide
Eli Lilly and Company
Phase 2BB
Pembrolizumab
Eli Lilly and Company
Phase 2BB

View all 28 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →